250602-05-2

Upstream product

• 335633-37-9 4-(hydroxyimino)-4-phenylbutylamide 
• 250602-53-0 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole 
• 79-37-8 oxalyl dichloride 
• 250601-04-8 (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutanoic acid 
• 250602-52-9 {4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}methanol 
• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 

Relevant academic research and scientific papers

ABC EXPRESSION PROMOTERS

The ABCA1 mRNA expression-promoting agent, LXRα mRNA expression-promoting agent, ABCG1 mRNA expression-promoting agent, cholesterol efflux-promoting agent, cholesteryl ester accumulation-inhibiting agent, ACAT-1 mRNA expression-inhibiting agent and CEH mRNA expression-promoting agent of the present invention are excellent in the ability to control cholesterol distribution in the body and have low toxicity.

Process for the preparation of oxyiminoalkanoic acid derivatives

The present invention provides, as an industrially advantageous production method, a method of producing a compound represented by the formula (III)

Neovascularization inhibitors

An angiogenesis inhibitor containing a compound represented by the formula wherein R4 is an optionally substituted hydrocarbon group and the like; Xa is a bond and the like; k is an integer of 1 to 3; Ya is an oxygen atom and the like; ring Ea is a benzene ring optionally having additional substituent(s); p is an integer of 1 to 8; R5 is a hydrogen atom and the like; q is an integer of 0 to 6; r is 0 or 1; R8 is a hydroxy group and the like; and R6 and R7 are hydrogen atoms and the like, or a salt thereof is useful as an agent for the prophylaxis or treatment of tumor and the like.

BODY WEIGHT GAIN INHIBITORS

An agent for inhibiting body weight gain derived from a PPARγ agonist-like substance, which contains a PPARδ agonist-like substance, is useful for the treatment of diabetes and the like.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.